GSE242140

Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Aim of this study was to explore the effect of 12-week pomegranate-juice consumption on the global transcriptional profile in individuals with inflammatory bowel disease (IBD) in clinical remission.

Overall design

Transcriptomic response was measured in circulating peripheral blood mononuclear cells (PBMCs) at baseline (t0) and after 12 weeks (t1) of intervention with pomegranate juice (seven IBD patients) or placebo (three IBD patients)

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
20 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study. Molecular nutrition & food research, 2025
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Ulcerative colitis 14 samples
  • Likely control group Vehicle control 6 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biofluid. Comparison suitability: 0%.
  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 40255128.
  • Publication context: Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.. Molecular nutrition & food research, 2025. PMID 40255128. DOI 10.1002/mnfr.70067.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

110 fields

Sample Group Preview

20 rows shown
Show Hide
Study totals: Case 14 | Control 6 | Unassigned 0 | Excluded 0 | Ambiguous 0 20 rows shown
Group Role Accession Title Source / characteristics Reason
Ulcerative colitis Case GSM7749606 PBMC_t0_POMJ_patient01 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 01 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749607 PBMC_t1_POMJ_patient01 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 01 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749610 PBMC_t0_POMJ_patient03 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 03 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749611 PBMC_t1_POMJ_patient03 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 03 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749612 PBMC_t0_POMJ_patient04 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 04 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749613 PBMC_t1_POMJ_patient04 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 04 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749614 PBMC_t0_POMJ_patient05 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 05 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749615 PBMC_t1_POMJ_patient05 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 05 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749620 PBMC_t0_POMJ_patient09 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 09 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Ulcerative colitis Case GSM7749621 PBMC_t1_POMJ_patient09 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 09 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Case marker detected.
Crohn's disease Case GSM7749622 PBMC_t0_POMJ_patient10 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 10 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Crohn's disease Case marker detected.
Crohn's disease Case GSM7749623 PBMC_t1_POMJ_patient10 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 10 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Crohn's disease Case marker detected.
Crohn's disease Case GSM7749624 PBMC_t0_POMJ_patient14 Peripheral blood mononuclear cells, t0, pomegranate juice, patient 14 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Crohn's disease Case marker detected.
Crohn's disease Case GSM7749625 PBMC_t1_POMJ_patient14 Peripheral blood mononuclear cells, t1, pomegranate juice, patient 14 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Female; Disease: Crohn's disease Case marker detected.
Vehicle control Control GSM7749608 PBMC_t0_pbo_patient02 Peripheral blood mononuclear cells, t0, placebo, patient 02 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Sample-local control marker detected.
Vehicle control Control GSM7749609 PBMC_t1_pbo_patient02 Peripheral blood mononuclear cells, t1, placebo, patient 02 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Sample-local control marker detected.
Vehicle control Control GSM7749616 PBMC_t0_pbo_patient06 Peripheral blood mononuclear cells, t0, placebo, patient 06 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Crohn's disease Sample-local control marker detected.
Vehicle control Control GSM7749617 PBMC_t1_pbo_patient06 Peripheral blood mononuclear cells, t1, placebo, patient 06 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Crohn's disease Sample-local control marker detected.
Vehicle control Control GSM7749618 PBMC_t0_pbo_patient07 Peripheral blood mononuclear cells, t0, placebo, patient 07 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Sample-local control marker detected.
Vehicle control Control GSM7749619 PBMC_t1_pbo_patient07 Peripheral blood mononuclear cells, t1, placebo, patient 07 Tissue: Peripheral blood mononuclear cells (PBMCs); Gender: Male; Disease: Ulcerative colitis Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.